阅读说明：本技术 奥扎莫德加成盐晶型、制备方法及药物组合物和用途 (Crystal form of addition salt of ozapimod, preparation method, pharmaceutical composition and application ) 是由 盛晓红 盛晓霞 郑剑锋 于 2017-04-07 设计创作，主要内容包括：公开了奥扎莫德加成盐晶型,与已知的奥扎莫德固体形态相比,其具有一种或多种改进的特性。还公开了奥扎莫德加成盐晶型的制备方法、其药物组合物、及其用于制备在医学上需要选择性鞘氨醇-1-磷酸酯受体的调节、活化、激动、抑制或拮抗的病症或不良状况的药物中的用途。<Image he="378" wi="700" file="DDA0002262938450000011.GIF" imgContent="drawing" imgFormat="GIF" orientation="portrait" inline="no"></Image>(Disclosed are crystalline forms of an ozatimod addition salt having one or more improved properties compared to known solid forms of ozatimod. Also disclosed are processes for the preparation of the azamod addition salt crystalline forms, pharmaceutical compositions thereof, and their use for the preparation of medicaments for conditions or disorders for which modulation, activation, agonism, inhibition, or antagonism of a selective sphingosine-1-phosphate receptor is medically indicated.)